The most common immune checkpoints include the following. Due to the inhibitory effects of CTLA-4, PD-1, and PD-1 ligands on the immune response, researchers early on proposed that blocking these ...

From these data, the researchers discovered that patients in the PD-1 blockade group, who were treated with a CTLA-4 blockade in prior cancer therapy outside of the study, had a dulled immune response ...

Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...

4, 7 and 10) and/or 0.2 mg/dose CTLA-4-Ig (days 0, 2, 4 and 6 after transplantation). Control recipients received 0.25 mg/dose hamster IgG (days 0, 2, 4, 7 and 10). The grafts were observed daily.

Hayashi. The team assessed the soluble forms of immune checkpoint molecules, PD-L1, PD-1, and CTLA-4 in the blood samples of patients with advanced NSCLC before PD-1/PD-L1 blockade therapy.

In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, ...

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

Individually, colistin decreases the effect of anti-CTLA-4 therapy in MCA205 tumors, while ampicillin, metronidazole, and vancomycin decrease responses to anti-PD-L1 therapy in MC38 tumors.